Retroperitoneal Sarcoma
Conditions
Keywords
Retroperitoneal Sarcoma, Surgery, Radiotherapy
Brief summary
Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center.
Detailed description
Retroperitoneal Sarcoma (RPS) which is a rare disease which incidence is 1.79/100,000. The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult. It was known to sacrifice one side kidney will improve the resection rate. To this days, successful surgical resection was still the gold standard that provide most benefit in overall survival. To reach that goal, pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging effect and improved the respectability but with limited benefit. Herein, investigators conducted this study to find the best way to achieve successful surgical resection and prognostic factor analysis.
Interventions
PROCEDUREtumor wide excision
patients received properative or post-operative radiotherapy
Sponsors
Taichung Veterans General Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital
Exclusion criteria
* the patient did not receive complete tumor excision in our hospital * the pathological report yielded not malignancy tumor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | The proportion of patients still alive at 1 year, 3 years, and 5 years after treatment. | After treatment, patients will undergo long-term follow-up to record their survival status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | The rates of local recurrence, regional recurrence, or distant metastasis at 1 year, 3 years, and 5 years after treatment. | Progression defined as local, regional, or distant metastasis |
Other
| Measure | Time frame | Description |
|---|---|---|
| The resectability of preoperative embolization | From the start of preoperative evaluations to the day of surgery, it typically spans 7 days. | Preoperative embolization for assessing resectability combines radiology, angiography, and transcatheter arterial embolization (TAE). Initially, imaging techniques such as X-rays or CT scans are used to understand the characteristics of the lesions. Then, angiography is employed to observe the tumor's blood supply. Finally, TAE not only evaluates the vascular supply to the tumor but also helps reduce its size through embolization, enhancing resectability. The comprehensive results of these assessments contribute to developing a safe and effective surgical plan. |
| The value of eGFR in renal function | Period from date before surgery to the date one year after suregry | eGFR is an important biomarker used to assess kidney function and monitor renal health. It represents the volume of blood filtered by the glomeruli per minute, typically expressed in milliliters per minute (mL/min). A venous blood sample will be collected and analyzed in the laboratory to determine the value. |
Countries
Taiwan
Outcome results
None listed